The cycle's central tension: capability is rising, capacity is falling, and the institutional bridges (reimbursement architectures, regulatory frameworks) are racing to close the gap.
Healthcare's central problem in 2026 is not lack of innovation. It is lack of clinicians to use it. New AI devices, GLP-1 launches and digital therapeutics are arriving faster than the workforce being lost to retirement, burnout and demographic decline.
Three institutional fixes are in motion: tighter drug-price reform on both sides of the Atlantic, a maturing AI-and-medical-device regulatory architecture, and reimbursement of digital alternatives to clinical work. All three are real, all three are operational, and all three are running on a slower clock than the workforce is shrinking.
The one thing to take into the next meeting: human time inside the clinical system is now the binding constraint on every operating plan. Treat clinician hours as scarce capital. Mental health is the early warning. Pricing and reimbursement strategy is the immediate exposure.
If your strategy assumes that more capable tools eventually meet the clinicians to use them, what happens if the clinicians do not arrive?
The 2026 evidence base says the gap is widening on a structural timetable, and the bridges (reimbursement, regulation, digital substitution) are running on a different and slower clock.
The cycle's central tension is structural: the health economy is producing more capable tools than ever, and fewer of the people needed to deliver care. The US FDA had authorised more than 1,350 AI-enabled medical devices by early 2026, roughly double the 2022 count (US FDA, structural anchor). Novo Nordisk's Wegovy pill exceeded 2 million US prescriptions in its first quarter of availability (Novo Nordisk Q1 2026 6-K, May 2026). The German DiGA scheme now reimburses 61 digital health applications with EUR 234m cumulative payouts and 861,000 utilisations (BfArM, structural anchor). On the other side: Germany needs at least 280,000 additional care workers by 2049 (Statistisches Bundesamt, structural anchor), and HRSA projects a US physician shortage of 141,160 by 2038, with primary care carrying 70,610 of that gap (HRSA, structural anchor). Two clocks, running in opposite directions.
Three institutional bridges are visible, each on its own clock. Reimbursement reform: the IRA's Maximum Fair Prices took effect for the first ten Medicare-negotiated drugs on 1 January 2026 at an average 38 percent discount, with 15 more drugs at 62 percent average discount queued for 1 January 2027 (CMS, structural anchor; CMS, structural anchor); Germany's GKV-BStabG draft law projects nearly EUR 20bn savings in 2027 and EUR 42bn by 2030 (Global Policy Watch, April 2026); NICE raised its UK QALY threshold to GBP 25,000-35,000 from April 2026, its first move since 1999 (NICE, March 2026). Regulatory architecture: the EU AI Act binds standalone Annex III AI from 2 August 2026 and embedded AI in MDR Class IIb/III from 2 August 2027 (MedDeviceGuide, February 2026); EUDAMED becomes mandatory on 28 May 2026 (Celegence, January 2026); the EU Joint Clinical Assessment expands to all medicines by 2030 (ICON plc, March 2026). Digital substitution: where clinicians do not exist, digital therapeutics, ambient monitoring and reimbursed home-based care are stepping in, most visibly in mental health and in chronic disease management via the CMS ACCESS Model launching 5 July 2026 (CMS, structural anchor).
There is a trap inside the bridge. The reimbursement architectures themselves (DiGA, PECAN, CMS ACCESS, JCA) all require clinical-evidence programmes that are clinician-time-intensive, so the capability-capacity gap reproduces itself inside the very mechanism designed to close it. The leadership-level insight: the bottleneck of the late 2020s is not capital, not regulatory clarity, and not technology readiness. It is human time inside the clinical system. Every operating decision in the next 18 months should be evaluated against that constraint.
The synthesis assumes capacity erodes faster than capability matures. If the EU AI Act omnibus deferral is formally adopted (pushing Annex III to December 2027 and embedded-AI to August 2028) and the CMS ACCESS Model achieves rapid adoption inside 18 months, the policy bridges could narrow the gap on a much faster timetable than the labour-supply data suggest. The falsifying signal would be three or more consumer-grade ambient-sensing diagnostic devices receiving CMS coverage decisions inside 18 months. Conversely, the analysis could understate the capacity crisis if the demographic projections (Destatis, HRSA, IMARC) prove conservative, particularly if non-EU migration into European care workforces stalls on political grounds.
Each is developed below, with a decision posture, in the four Strategic Implications.
Four lenses on the same intelligence base, one per audience type. Each card surfaces the one question this cycle puts to that audience.
The shift: US RN supply meets only 90 percent of projected demand in 2026 with 8.06 percent of nursing demand going unmet (Prolink, February 2026); over 1 million US nurses are projected to retire by 2030 (AACN, structural anchor); Germany has 17,600 unfilled elderly-care and 15,000 hospital-nursing positions and only 19 applicants per 100 geriatric-nurse vacancies (Pflegenot Deutschland, January 2026); the labour data are now hard.
The question to brief: Which two services do we explicitly de-scope, partner-out, or substitute with digital therapeutics or home-based care in the next 18 months to free clinical time for the services we will not substitute?
The shift: The CMS ACCESS Model launching 5 July 2026 is the first US reimbursement architecture purpose-built for wearable and remote-monitoring device categories (CMS, structural anchor); BfArM lists 61 DiGAs with EUR 234m cumulative reimbursement (BfArM, structural anchor) and the scheme tightened to 20 percent performance-based pricing and Class IIb scope from 2026 (Inside EU Life Sciences, February 2026); the EU JCA second-year pipeline carries 11 medicines (ICON plc, March 2026); each architecture lowers the marginal post-approval revenue risk for products inside it.
The question to brief: Which two reimbursement-architecture-eligible categories carry the lowest clinical-evidence cost per unit of risk-adjusted revenue, and what is the named clinical-evidence programme to land an asset inside one by FY27?
The shift: The EU regulatory architecture has three independent clocks running in parallel into 2026 and 2027: AI Act binding dates (MedDeviceGuide, February 2026), EUDAMED mandatory 28 May 2026 (Celegence, January 2026), JCA second-year operations and mandatory orphan from 2028 (ICON plc, March 2026); the FDA's LDT final rule was vacated by federal court in April 2025 and rescinded by FDA in mid-to-late 2025 (Sidley Austin, structural anchor; MedTech Dive, structural anchor), opening a US versus EU divergence on diagnostics oversight.
The question to brief: Which one to two upcoming regulatory milestones, if sequenced or deferred, would materially reduce the cumulative compliance load on the SME manufacturer base without weakening patient-protection outcomes?
The shift: The 2026 IRA Maximum Fair Prices propagate into payer formulary economics and reference-pricing exposures (CMS, structural anchor); GLP-1 spend continues to rise as Wegovy pill exceeds 2 million US prescriptions in its launch quarter (Novo Nordisk, May 2026); NHS Talking Therapies waiting lists exceeding three years (Mad in the UK, February 2026) create regulatory and political pressure that translates into specific operational obligations.
The question to brief: What is the worst-credible FY27 EBITDA scenario combining a 15 percent step-down in negotiated-drug revenue (or pharmaceutical spend), continued GLP-1 spend growth, and the operational cost of converting clinical pathways to digital-first or home-based delivery?
The cycle's signals are organised into six themes, ranked by impact on near-term operational decisions across the health, life sciences and care economy. Immediate: changes the FY27 plan, the corporate structure or the proposition. Near-Term: changes competitive position over the next twelve months. Longer-Range: a multi-year structural factor to track and revisit each cycle.
The clinical workforce is structurally and visibly insufficient to deliver the care that an ageing population now demands, across all four heartland markets of the developed health economy. Germany, the US, the UK and Japan are all running the same arithmetic: more people needing care, fewer people in the workforce, an ageing existing workforce retiring out, and migration flows that are politically constrained. The labour data are now hard, not forecast. For health systems, the practical implication is that the alternative to redesigning care delivery is service rationing. For investors and operators, it is that any clinical-time-intensive operating model is on a tightening cost curve.
Sources: Destatis (DE care, structural anchor), HRSA (US physicians, structural anchor), Prolink (US RN, February 2026), IMARC (Japan, February 2026), AACN (US retirements, structural anchor), Pflegenot (DE vacancies, January 2026).
The workforce projections are sensitive to migration policy and to AI-enabled productivity gains within the existing workforce; an aggressive expansion of regulated foreign-trained nurse recognition, paired with FDA-cleared and EU-validated AI tools that meaningfully expand each clinician's caseload capacity, could close more of the gap than the headline numbers suggest. The competing reading is that the gap is partly a productivity problem masquerading as a labour-supply problem, and that the operating model redesign should target output per clinician-hour rather than additional clinician hours.
The pricing architecture for innovative medicines tightened materially on 1 January 2026 and tightens again on 1 January 2027. The US Inflation Reduction Act's Maximum Fair Prices for the first ten Medicare-negotiated drugs are now effective with a minimum 38 percent discount on 2023 list prices; the second cohort of 15 drugs has Maximum Fair Prices announced and effective from 1 January 2027 with a 62 percent average discount. Germany is pushing through the GKV-Beitragssatzstabilisierungsgesetz with projected savings of EUR 20bn in 2027 and EUR 42bn by 2030. NICE raised its UK cost-effectiveness threshold from April 2026, the first increase since 1999. The cumulative effect on pharma gross margin is meaningful, and the international reference pricing dynamic propagates the US and German step-downs into adjacent markets.
The headline IRA discounts apply to a small set of high-revenue drugs and the operational impact is concentrated in a handful of manufacturers; the German GKV-BStabG is still a draft and the parliamentary path is uncertain; the NICE threshold change cuts the other way for manufacturers (it admits more medicines for reimbursement). The competing reading is that the cumulative pricing impact is real but narrowly concentrated, and that pharma's overall portfolio economics are still dominated by patent-cliff dynamics and pipeline replacement rather than by negotiated-price pressure on individual products.
AI-enabled medical devices have moved from regulatory clearance backlog to reimbursement architecture build-out. The US FDA had authorised over 1,350 AI-enabled devices by early 2026, about double the 2022 count; the EU AI Act binds in two waves (August 2026 for Annex III standalone systems, August 2027 for embedded AI in MDR Class IIb/III); the CMS ACCESS Model launches 5 July 2026 with outcome-aligned reimbursement for technology-enabled chronic care; the EU MDCG classification guidance was reissued in April 2026; the German DiGA scheme extended scope to Class IIb digital medical devices from 2026. The story has shifted from authorisation pipelines to whether the authorised tools actually reach patients on terms that change the workforce-capacity arithmetic in Theme 1.
The FDA authorisation count is concentrated in radiology and cardiology imaging algorithms and does not translate evenly into deployed clinical use. The CMS ACCESS Model is a Medicare programme; the binding question is whether commercial payers and Medicare Advantage plans adopt parallel arrangements. The omnibus deferral signal on the EU AI Act, if confirmed, weakens the urgency of regulatory compliance investment. The competing reading is that AI diagnostics will continue to clear regulatory pipelines faster than they reach deployed reimbursed clinical use; the bottleneck in the late 2020s is implementation, not authorisation.
Mental health is the live demonstration of the capability-capacity gap. Demand is structurally rising (global anxiety cases reached 359.2 million and depression 332.4 million in 2021 with forecasts of over 515 million and 466 million respectively by 2040). Supply is structurally constrained (NHS Talking Therapies waiting lists exceeding three years; the post-assessment wait alone can be 6 to 18 months). Digital therapeutics have stepped into the gap: mental health is the largest single category in the German DiGA scheme with 5 listed apps each for depression and anxiety, the May 2026 UK Mental Health Strategy consultation positions DTx as part of the structural response, and 2026 changes to DiGA make mental health DTx a more scrutinised but more capacious reimbursement channel. The case shows what happens elsewhere when capability outruns capacity: digital substitution scales fast under tight evidence requirements.
Digital therapeutics have strong reimbursement architecture but mixed real-world adoption and uneven clinical-evidence support; the systematic review evidence base on DiGA mental health apps remains in development. The competing reading is that the digital-substitution-of-clinical-care narrative overstates DTx effectiveness and risks substituting an under-evidenced intervention for an evidence-based one. The DiGA scheme's 2026 tightening (mandatory success measurement, 20 percent performance-based pricing) is partly a response to this concern.
GLP-1 medicines are the single largest source of system-level pharmacy spend growth and a meaningful budget-management challenge for every major payer. Wegovy's pill formulation exceeded 2 million US prescriptions in its launch quarter (strongest-ever GLP-1 volume launch), Mounjaro and Zepbound have pulled ahead on combined 2025 sales, and Wegovy HD and orforglipron arrive in 2026. Indications are expanding (Mounjaro MACE reduction in T2DM awaiting FDA decision, sleep apnoea and cardiovascular indications already widening the eligible pool, possible Alzheimer's trials reading out). The structural question for the health economy is whether GLP-1 spend is a sustained budget line, a payer-managed peak, or a category that gets caught in IRA Cycle 3 or 4 negotiation.
The 8 percent CER decline in Novo's Q1 2026 total GLP-1 sales suggests the category peak may already be visible on the leading product family. Payer management tools (step therapy, prior authorisation, indication-specific coverage decisions) are tightening; the IRA Cycle 3 or 4 negotiation could include semaglutide or tirzepatide; the manufacturers' capacity-expansion trajectory may overshoot demand if payer constraint bites. The competing reading is that the GLP-1 story is a 2026 to 2027 budget challenge and a 2028 to 2030 normalisation rather than a sustained decade-long spend escalator.
Three independent regulatory clocks are now running in parallel across the major markets, and a manufacturer operating in more than one jurisdiction has to navigate them simultaneously. The EU has the AI Act, the MDR/IVDR transition with EUDAMED becoming mandatory on 28 May 2026, and the second-year operations of the EU Joint Clinical Assessment. The US has the IRA negotiation cycles, the FDA AI/ML framework, and the now-vacated FDA LDT final rule which leaves laboratory-developed tests in regulatory limbo with FDA enforcement discretion. The cumulative compliance load on the SME manufacturer base is the binding operational question; mid-size manufacturers have to triage which jurisdictions they prioritise.
Sources: MedDeviceGuide (AI Act, February 2026); Celegence and Arnold and Porter (EUDAMED, January-February 2026); ICON plc (JCA, March 2026); Sidley Austin and MedTech Dive (FDA LDT, structural anchors); NICE (March 2026); CMS (IPAY 2027, structural anchor).
Regulatory convergence often gets framed as a constraint but actually creates an opportunity for well-prepared incumbents to consolidate market share against under-resourced challengers. The omnibus deferral on the EU AI Act would substantially reduce the parallel-pathway burden; the FDA LDT rescission similarly reduces a major US compliance overhead. The competing reading is that the convergence narrative overstates the manufacturer pain because the actual binding constraints are Notified Body capacity and clinical-trial throughput, and both will improve as the cycle matures.
Four decisions turn this cycle's signals into the operating plan. Each names the move, a horizon and a decision posture.
Health delivery boards should treat human clinical time as the explicitly named binding constraint in the next operating plan, and force every initiative to compete inside that constraint. The implication is that the next-year budget should fund explicit substitution programmes (digital therapeutics for mental health, ambient monitoring for chronic disease, AI triage for radiology) rather than headline-rate clinician recruitment that the workforce data say will not deliver. The Decide posture reflects that the workforce evidence is now operationally binding inside the FY27 plan.
Action: by 31 December 2026, each health delivery organisation's Executive Committee identifies two named clinical services for explicit digital or home-based substitution, with named clinician-hour savings, and one named service for de-scoping or partnership delivery.
Decide Draws on Themes 1 and 4Pharma and life-sciences leadership should re-baseline FY27 pricing strategy explicitly against the legislated 2026 IRA prices and the 2027 step-down, plus the German GKV-BStabG pathway. International reference pricing propagates the US and German step-downs into adjacent markets; the practical question is which products receive what reference-pricing treatment and which markets get prioritised for launch. The Prepare posture reflects that the FY27 baseline is now known but the operational response (channel mix, market sequencing, indication prioritisation) is a 12-month workstream.
Action: by 31 March 2027, pharma Executive Committees deliver a re-baselined FY27 pricing and channel plan documenting the IRA, GKV-BStabG and NICE-threshold impact on every product above EUR 100m revenue and naming three operational responses (channel mix, indication sequencing, market prioritisation).
Prepare Draws on Themes 2 and 5Healthtech investors and operators should authorise an explicit filing programme that takes two device or DTx products through one of the four operational reimbursement architectures (DiGA, PECAN, CMS ACCESS or the EU JCA pathway for medicines). The clinical-evidence work is a 12 to 18 month programme but the architecture is operational now; the longer the filing decision is deferred, the more competitive ground is conceded to filings already in flight. The Prepare posture reflects the cycle-2 trigger condition (a CMS coverage decision under ACCESS for a non-Philips ambient-sensing device) that would escalate this to Decide.
Action: by 30 September 2027, healthtech investor and operator portfolios document two named products filed into named reimbursement architectures, with documented clinical-evidence dossier and projected first-revenue dates.
Prepare Draws on Themes 3, 4 and 6Regulators and operators should monitor the four regulatory milestones likely to shift in the next 12 months (EU AI Act omnibus deferral vote, EUDAMED activation 28 May 2026 and post-activation Notified Body capacity, first JCA report mid-2026, FDA LDT regulatory direction post-rescission) and stand up a response capability that can act inside 6 months of each milestone landing. The Monitor posture reflects that none of these milestones are confirmed; the trigger to escalate is the first formal Council vote on the AI Act omnibus or a CMS coverage decision under ACCESS for a non-incumbent device category.
Action: by 31 December 2026, named regulatory and operations leaders publish a monitoring dashboard tracking the four milestone categories with explicit decision-triggers documented for each.
Monitor Draws on Themes 3 and 6The two critical uncertainties shaping the next 2 to 5 years are the pace at which digital and AI-enabled substitution narrows the capability-capacity gap, and the pace at which pricing pressure (IRA, GKV-BStabG, JCA-driven price negotiation) compresses pharma and devicemaker gross margins. The four scenarios below are planning aids, not forecasts.
Digital substitution scales rapidly: CMS ACCESS achieves greater than 10 percent year-on-year participating-provider growth from 2027; DiGA reaches over 100 listed apps with greater than 2m utilisations; EU AI Act binds on schedule with notified-body capacity expanding to absorb the load. Pricing pressure simultaneously tightens: IRA Cycles 3 and 4 land on schedule with consistent 60 percent average discounts; the German GKV-BStabG passes; international reference pricing propagates fully. Outcome: rapid digital substitution offsets clinical-time capacity loss, but pharma and devicemaker gross margins compress 200 to 400 basis points; the system absorbs the capability-capacity gap at significant industry cost.
Digital substitution scales as in Scenario 1 but pricing pressure softens: EU AI Act omnibus passes with broad scope; the German GKV-BStabG stalls in committee; NICE threshold change moderates UK pricing impact; IRA Cycle 3 timing slips. Outcome: pharma and devicemaker margins hold or expand; digital-substitution investment proceeds without the offset of margin compression; manufacturer R&D spend on AI and DTx accelerates; the capability-capacity gap closes inside 24 months. Best-case for incumbent industry; the system adapts faster than pessimists predicted.
Digital substitution underdelivers: CMS ACCESS first-year cohort below 50 providers; DiGA scheme tightening cuts the listed-app count; EU AI Act omnibus fails and adoption hesitancy among health systems persists. Pricing pressure tightens as in Scenario 1. Outcome: capacity gap widens faster than substitution closes it; service rationing materialises in UK and German systems first; pharma margins compress without the offset of new revenue from reimbursed digital adjacencies. Worst-case for industry margins and for patient access; political pressure intensifies.
Digital substitution underdelivers but pricing pressure softens; the system absorbs the capability-capacity gap through political concession to incumbent pricing and selective service rationing. Outcome: the structural challenge persists but neither side wins decisively; the next decade looks much like the last one with marginal worsening. The capability-capacity gap continues to widen but slowly; political pressure remains a near-constant background.
This cycle does not contemplate a structural change in the surgical robotics market. The category is concentrated, the engineering and regulatory cycle is long, and the cycle's central tension (capability-capacity gap, pricing pressure) does not bear on surgical robotics in the same way. Intuitive Surgical, Medtronic Hugo and Johnson and Johnson Ottava continue to occupy the space without material new entrant pressure.
Reinstate if: a single-port robotic system from CMR Surgical, Asensus or Distalmotion lands a major hospital-system contract worth greater than USD 200m, or a Chinese surgical robotics manufacturer files for FDA clearance with credible clinical-evidence backing.
This cycle does not contemplate an AI-drug-discovery platform delivering a regulatory approval for a meaningfully novel indication. Insilico, Recursion, Generate, Exscientia and the AI-discovery cohort remain in the pipeline-stage validation phase; the 18-to-24-month outlook anticipates incremental pipeline progress but not a binary breakthrough.
Reinstate if: an AI-discovered molecule lands a Phase 3 readout on a meaningfully novel indication, or an AI-discovery platform announces a major-pharma acquisition above USD 5bn.
This cycle does not contemplate a step-change in China's outbound life-sciences licensing posture. BeiGene, Innovent and Akeso continue to negotiate global licensing deals at the pace of the past 24 months; the audience-level cycle does not need a binary view here.
Reinstate if: a US Executive Order materially restricts US capital flows into Chinese biotech, or China NMPA announces a step-change in approval-pathway transparency for foreign-developed medicines.
This briefing draws on 36 verified sources, gathered under a soft 6-month recency window (publications from 2 December 2025 onward), with 14 structural anchors (federal demographic projections, peer-reviewed evidence bases, canonical institutional reference pages, foundational legal precedent).
Source tiers: Tier 1, governments, regulators and intergovernmental bodies. Tier 2, think-tanks, academic institutes, major consultancies and quality data providers. Tier 3, quality journalism and specialist trade press. Tier 4, vendor, company and practitioner sources, used only as directional corroboration.
| Source | Tier | Date | Key claim used |
|---|---|---|---|
| Statistisches Bundesamt, Pflegekräftevorausberechnung 2049 | Tier 1 | Structural anchor | Germany requires at least 280,000 and possibly up to 690,000 additional care workers by 2049. |
| Pflegenot Deutschland, Personalmangel Pflege 2026 | Tier 3 | Jan 2026 | 17,600 unfilled elderly-care and 15,000 hospital-nursing positions in 2024; 19 applicants per 100 geriatric-nurse vacancies; 27,000 foreign care workers added in 2024. |
| HRSA Bureau of Health Workforce | Tier 1 | Structural anchor | US physician shortage of 141,160 by 2038 with primary care carrying 70,610; family medicine alone short 39,060. |
| AACN, Nursing Shortage Fact Sheet | Tier 2 | Structural anchor | Over 1 million US nurses projected to retire by 2030; 50% of RNs are 50 and older; BLS projects 189,100 RN openings annually. |
| IMARC Group, Japan home healthcare market | Tier 2 | Feb 2026 | Japan home healthcare CAGR 7.8% 2026-2034 to USD 57.69bn; aging rate 29.3% in 2024 projected 33% by 2037; 690,000 care worker shortage by 2040. |
| Prolink, 8.06% US nursing demand unmet | Tier 3 | Feb 2026 | RN supply meets only 90% of projected demand in 2026; 8.06% nursing demand unmet. |
| Source | Tier | Date | Key claim used |
|---|---|---|---|
| CMS, Selected Drugs and Negotiated Prices (IPAY 2026/2027) | Tier 1 | Structural anchor | Ten Cycle 1 MFPs effective 1 January 2026; USD 6bn annual Medicare saving; minimum 38% off 2023 list prices. |
| CMS, IPAY 2027 MFPs announcement | Tier 1 | Structural anchor | 15 drugs in Cycle 2 with MFPs announced 25 November 2025; effective 1 January 2027; 62% average discount. |
| Manatt, IPAY 2027 discount analysis | Tier 2 | Structural anchor | 62% average discount confirmed; gross-margin impact on patent-protected portfolios at major manufacturers. |
| Global Policy Watch (Covington), GKV-BStabG | Tier 2 | Apr 2026 | EUR 20bn 2027 savings projection; EUR 42bn+ by 2030; sharpens AMNOG; tender-style contracts pilot through 2030. |
| NICE, Cost-effectiveness threshold change | Tier 1 | Mar 2026 | QALY threshold rises from GBP 20-30k to GBP 25-35k from April 2026, first increase since 1999. |
| OHE, NICE threshold analysis | Tier 2 | Apr 2026 | Economic analysis of threshold change; expected industry response. |
| Cytel, NICE methods change | Tier 2 | Mar 2026 | Operational implications for HTA-submission strategy. |
| Source | Tier | Date | Key claim used |
|---|---|---|---|
| US FDA, AI in SaMD | Tier 1 | Structural anchor | 1,350+ AI-enabled devices authorised by early 2026; PCCP final guidance Dec 2024. |
| MedDeviceGuide, EU AI Act for medical devices | Tier 2 | Feb 2026 | Annex III binding August 2026; Article 6(1) August 2027; omnibus deferral signalled. |
| CMS, ACCESS Model | Tier 1 | Structural anchor | Launches 5 July 2026 for 10 years; outcome-aligned payment; wearables the enabling device class. |
| EC DG SANTE, MDCG 2021-24 rev.1 | Tier 1 | Apr 2026 | Current canonical EU MDR classification guidance. |
| BfArM, DiGA programme statistics | Tier 1 | Structural anchor | 61 DiGAs listed Feb 2026; EUR 234m reimbursed; 861,000 utilisations. |
| Inside EU Life Sciences, DiGA 2026 changes | Tier 2 | Feb 2026 | Mandatory success measurement Q3 2026; 20% performance pricing; Class IIb scope. |
| Source | Tier | Date | Key claim used |
|---|---|---|---|
| Mad in the UK, NHS talking therapy waiting times | Tier 3 | Feb 2026 | Three-year+ waiting lists; 6-18 month post-assessment wait for therapy. |
| NHS England, Mental health access standards | Tier 1 | Structural anchor | NHS targets: 75% within 6 weeks of referral; 95% within 18 weeks. |
| Smart Therapy, UK Mental Health Strategy 2026 | Tier 3 | May 2026 | Cross-government consultation launched 15 May 2026; once-in-a-generation reform; digital substitution components. |
| MTR Consult, GKV DiGA utilisation report | Tier 2 | Feb 2026 | Mental health most common DiGA category; 5 depression, 5 anxiety apps listed. |
| When Notes Fly, Mental Health Statistics 2026 | Tier 4 | Jan 2026 | 970m global mental health disorder burden; 280m depression; 301m anxiety; 75% in LMICs untreated. |
| ScienceDirect, GBD anxiety/depression forecast to 2040 | Tier 2 | Structural anchor | 2021: 359.2m anxiety, 332.4m depression; 2040 forecast: over 515m / 466m. |
| MobiHealthNews, new DiGA mental health app | Tier 3 | Feb 2026 | Documents ongoing expansion of mental-health DTx reimbursement in Germany. |
| Source | Tier | Date | Key claim used |
|---|---|---|---|
| Novo Nordisk, Q1 2026 SEC 6-K | Tier 1 | May 2026 | Wegovy pill US launch >2m prescriptions Q1; Wegovy HD US launch expected April 2026; GLP-1 sales -8% CER; obesity care +44% CER. |
| Heygotrade, LLY vs NVO 2026 GLP-1 comparison | Tier 3 | Apr 2026 | Mounjaro/Zepbound pulled ahead of Ozempic/Wegovy on combined 2025 sales; orforglipron Q2 2026 FDA decision. |
| Prime Therapeutics, GLP-1 pipeline update Feb 2026 | Tier 2 | Feb 2026 | Payer-side perspective on pipeline, capacity, indication expansion (CV, sleep apnoea), management strategy. |
| Novo Nordisk, Form 6-K Feb 2026 | Tier 1 | Feb 2026 | Q4 2025 and full-year 2025 results; 2026 outlook on GLP-1 capacity and competitive positioning. |
| Source | Tier | Date | Key claim used |
|---|---|---|---|
| QbD Group, EU MDR bottleneck 2026 | Tier 2 | Jan 2026 | <40 NBs under MDR, ~19 under IVDR; 13-18 month review queues; capacity is the binding constraint. |
| Arnold and Porter, EU medical device shake-up | Tier 2 | Feb 2026 | EUDAMED four-module mandatory 28 May 2026; Actor Registration and SRN required. |
| ICON plc, EU HTAR first year | Tier 2 | Mar 2026 | JCA operational 12 Jan 2025; 11 products under review Jan 2026; mandatory orphan 2028, all medicines 2030. |
| Sidley Austin, FDA LDT rule struck down | Tier 2 | Structural anchor | April 2025 federal district court vacated FDA LDT final rule; Loper Bright precedent test. |
| MedTech Dive, FDA rescinds LDT rule | Tier 3 | Structural anchor | FDA formally rescinded LDT final rule mid-to-late 2025; LDTs revert to CMS-CLIA with FDA enforcement discretion. |
| Celegence, EUDAMED mandatory May 2026 | Tier 2 | Jan 2026 | Four EUDAMED modules functional from EC announcement 27 Nov 2025; mandatory compliance 28 May 2026. |
This appendix records every claim in this briefing that goes beyond what a cited source literally states.
This is the inaugural sample briefing on the Health, Life Sciences and Care Systems topic; there is no prior cycle to reference. Future cycles on this topic will populate this section.
Prepared by Shaping Tomorrow: 2 June 2026